Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Juvenile Idiopathic Arthritis Associated Uveitis

Interventions

DRUG

Tocilizumab

"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"

Trial Locations (1)

Oregon Health & Science University, Portland